American Association for Cancer Research

Stand Up To Cancer Research Funding Opportunities

Bookmark and Share

 CALL FOR PROPOSALS


Stand Up To Cancer-Cancer Research UK Translational Research Fellowship

The American Association for Cancer Research (AACR), on behalf of Stand Up To Cancer (SU2C) and Cancer Research UK, is accepting applications for SU2C-Cancer Research UK Translational Research Fellowships that will offer up to $315,000 each in research funding.

The grants provides four years of research fellowship support to the most talented and promising early-career investigators in the United States and the United Kingdom who have completed their Ph.D. or clinical training and demonstrate clear potential to become leaders in their fields. Research projects must be translational in nature and address critical problems in cancers with the potential to deliver patient benefit.

Fellows funded through this initiative will gain translational research training in top U.S. and U.K. research institutions, allowing them to develop their own ideas and preparing them to establish and lead their own research groups, towards becoming outstanding leaders in their own fields. Proposals must include plans to promote new significant transatlantic collaborations and active exchange of knowledge and expertise between the United States and the United Kingdom.

APPLICATION DEADLINE

July 28, 2014, at 12 p.m. (noon) ET
Applications must be submitted online using the proposalCENTRAL website

START OF GRANT TERM
Feb. 1, 2015

ELIGIBILITY CRITERIA
The fellowship will be open to U.S.- and U.K.-based individuals who hold a Ph.D. and/or a medical degree. Individuals who hold a Ph.D. and/or a U.S. medical degree (M.D., D.O.) may apply. Individuals who hold both a U.K. medical degree and a Ph.D. may apply. By the start of the grant term, applicants must have completed their Ph.D. and/or medical degree and have less than a total of two years of postdoctoral or clinical research experience. Applicants must identify one qualified U.S. host laboratory and mentor and one qualified U.K. host laboratory and mentor. The work must be performed in two phases, one in the United States and one in the United Kingdom. Mentors should be established leaders in cancer research with a track record of success in mentoring postdoctoral or clinical research fellows.

Complete Program Guidelines and Submission Instructions are available below and on the proposalCENTRAL website.

Program Guidelines (Adobe Acrobat Reader is required)

INQUIRIES
Telephone: (267) 765-1049267-765-1049 
Fax: 267-765-1046
Email: SU2C@aacr.org

Sta Op Tegen Kanker Dream Team Translational Cancer Research Grant

The American Association for Cancer Research (AACR), on behalf of Stand Up To Cancer (SU2C) and the Dutch Cancer Society - KWF Kankerbesrtijding (KWF), is no longer accepting applications for a Sta Op Tegen Kanker Dream Team Translational Cancer Research Grant that will offer up to €6 million in research funding.

The grant provides four years of funding for a translational cancer research project that will address critical problems in patient care and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional team of expert investigators. Research projects must be designed to accelerate the application of new preventive, diagnostic or therapeutic agents to the clinic, and may focus on particular organ sites or on specialized research areas.

Proposals for the Sta Op Tegen Kanker Dream Team Translational Cancer Research Grant must describe plans indicating how the work will be translated into the clinic. To maximize creativity, innovation and collaboration, the projects should span multiple disciplines and use modern biological tools to attack research questions in a coordinated way.  

APPLICATION DEADLINE
April 1, 2014, at 12 p.m. (noon) ET

START OF GRANT TERM
Jan. 1, 2015 

ELIGIBILITY CRITERIA
The Dream Team leader must be from a research institute located in the Netherlands. Dream Team co-leader (optional) and principals can be from research institutes in any country. Each project must include at least two research institutes located in the Netherlands and at least one research institute outside the Netherlands. At least 50 percent of the grant funds must be allocated to research conducted in the Netherlands.


 

Since its launch in 2008, Stand Up To Cancer (SU2C) has funded a total of ten Dream Teams, one International Translational Cancer Research Team and 26 Innovative Research Grants, totaling more than $160 million. These grants encompass more than 700 scientists from 109 institutions involved in more than 140 clinical trials.

On May 28, 2009, one year after its launch, SU2C announced funding of five multi-institutional, cross-disciplinary, three-year “Dream Team” grants, totaling $73.6 million. Since then, SU2C has partnered with other renowned organizations to jointly fund Dream Teams focusing on specific areas of cancer research. In December 2011, SU2C and the Melanoma Research Alliance announced a new Dream Team that will receive $6 million over three years for translational research focusing on melanoma. In 2012, three new Dream Teams were announced focusing on prostate cancer (two Dream Teams in collaboration with the Prostate Cancer Foundation), and cancer immunology (one Dream Team in collaboration with the Cancer Research Institute). Each jointly funded grant will provide $10 million over three years for a total of $30 million. In April 2013, SU2C and the St. Baldrick's Foundation announced a new Dream Team that will receive $14.5 million over four years for translational research focusing on pediatric cancer.

In addition, on August 2, 2012, SU2C, in collaboration with Kankerbestrijding/The Dutch Cancer Society (KWF), announced recipients of a new Sta Op Tegen Kanker International Translational Cancer Research Grant. This grant provides funding of €1.2 million ($1.3 million U.S.) for four years. The funding mechanism represents a new, focused effort to affect advances in cancer research as rapidly as possible through the creation of collaborative, international translational cancer research “Team.”

Finally, through its Innovative Research Grants, SU2C has made an effort to support the next generation of extraordinary leaders in their quest to conquer cancer. These grants provide up to $750,000, over a three-year term, to early-career scientists whose novel, high-risk, high-reward research proposals may have significant potential for translational application. Thirteen grants were awarded in 2009, and 13 more in 2011 totaling $19.4 million.

 

 Updated: April 7, 2014